Frontiers in Microbiology, Biotechnology & Crop Science (FMBC)
ISSN: 3139-2741 (Online) | Vol. 02, Issue-01, Jan-June, 2026 | pp. 153-170

Nexus of Gut Microbiota, AI, 3d Bioprinting, Pathogens: Gut-Brain Axis, Epidemiology Global, India, Code to Living Tissue, Inflammatory Bowel, Crohn's Disease, Ulcerative Colitis, Colorectal Cancer

Yash Srivastav[1*], Shivani Singh[1], Kamini Prajapati[1], Stuti Verma[2] Vivek Kumar[1], Rajeev Kumar[1], Anubha Dhuriya[2]

[1]D.K.R.R Pharmacy College, Amberpur, Sitapur, Uttar Pradesh, India. 261303

[2]Aryakul College of Pharmacy and Research, Sitapur, Uttar Pradesh, India. 261303

***Corresponding Author E-mail: yashsrv.108@gmail.com**

Abstract:

In humans, the microbiota in the gut interacts with the host and the gut-brain axis to maintain the health of the gastrointestinal tract, metabolism, immunity, and brain processes. Inflammatory bowel illnesses (IBDs) include Crohn's disease and ulcerative colitis (UC) as well as colorectal cancer (CRC) are strongly correlated with microbial dysbiosis. The subject of microbiome research has been greatly impacted by recent advancements in artificial intelligence and 3D printing. These technologies hold great promise for better illness prognosis, biomarker identification, personalized diagnosis, and the modelling of tissues particular to individual patients. This paper explores the relationship of gut microbiota, pathogens, AI and 3D bioprinting with a particular emphasis on the epidemiology of IBD and colorectal cancer (CRC) on the global and Indian scales. The results of the research showed that microbial dysbiosis can cause many diseases through immune dysregulation, inflammation, and gut-brain axis disturbance. Machine learning-based analytics and human-derived organoids and 3D bio printed tissues appear to be extremely useful in developing precision medicine and translational gastroenterology.

Keywords: Gut Microbiota, Gut-Brain Axis, Artificial Intelligence, 3D Bioprinting, Pathogens, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Colorectal Cancer, Precision Medicine.

Received: Feb. 11, 2026 **Revised: March 21, 2026** **Accepted: April 19, 2026** **Published: June 25, 2026**

DOI: https://doi.org/10.64474/3139-2741.Vol2.Issue1.7

https://fmbc.nknpub.com/1/issue/archive

1. INTRODUCTION

The gut microbiota is one of the most well-known and highly researched areas of biomedical science, with a significant impact on gastrointestinal, metabolic, immunological and neurological health. Emerging research in the field of microbiomics has shown that the gut is not just a digestive system, but a very dynamic ecosystem where trillions of microorganisms communicate with the tissues and systems of the host. Rising evidence suggests a link between microbial dysbiosis (imbalance) and inflammatory bowel disease (IBD), Crohn's disease (CD), UC, and CRC, further solidifying the gut-brain axis as an important link between the two systems. Meanwhile, new opportunities for illness prediction, personalized medicine, tissue engineering, and personalized healthcare have been unlocked by developments in artificial intelligence (AI), human organoids, and 3D bioprinting technology. The review aims to examine the interplay between gut microbiota, pathogens, AI, and sophisticated bioengineering techniques, and how they contribute to the precision gastroenterology of the future.

1.1.Background Information and Context

A diverse and ever-changing community of microbes, the human gut microbiota plays a critical role in maintaining a healthy digestive tract, immune system, and nervous system. These microorganisms play a role in digestion, nutrient metabolism, synthesis of vitamins and energy production as well as protection against pathogenic microorganisms. Our knowledge and understanding of the gut microbiome have grown immensely in recent years thanks to the development of metagenomics and next-generation sequencing technologies that have shed light on the functions of the gut microbiome and its importance in shaping human health. Multiple diseases, including IBD, CD, UC, and CRC, have been associated with alterations in the variety and composition of bacteria, which are called microbial dysbiosis.



Figure 1: Communication Pathways Linking Gut Microbiota and Brain Function[1]

In addition, the gut-brain axis influences neurological functions, mood, stress responses, and cognition via its two-way communication system with the central nervous system, which includes neural, endocrine, immune, and metabolic components.

1.2.Objectives of the Review

The following are the research objectives of the study:

1. To examine the role of gut microbiota, pathogens, and the gut-brain axis in human health and disease.
2. To explore the contribution of microbial dysbiosis to inflammatory bowel disease (Crohn's disease and ulcerative colitis) and CRC.
3. To review the global and Indian epidemiology of inflammatory bowel disease and CRC.
4. To evaluate the applications of AI in microbiome research, disease prediction, and precision medicine.
5. To assess the potential of human organoids and 3D bioprinting in disease modeling, drug discovery, and personalized healthcare.
6. To identify current challenges, research gaps, and future directions in precision gastroenterology.

1.3.Importance of the Topic

The understanding of interactions between gut microbiota, pathogens, gut-brain axis, artificial intelligence and advanced tissue-engineering technologies is crucial to develop the next generation of healthcare solutions[2]. The rising prevalence of IBD and CRC globally, and emerging evidence of the contribution of microbial dysbiosis to the pathogenesis of IBD, warrant new methods of diagnosis and treatment. The application of biomarker analysis, human organoids, and 3D bioprinting technologies can revolutionize the discovery of novel biomarkers, personalized treatment approaches, drug screening, and regenerative medicine. Therefore, the convergence of microbiome science and computational intelligence and bioengineering paves the way for precision gastroenterology and personalized healthcare.

2. GUT MICROBIOTA, PATHOGENS, AND THE HUMAN GUT-BRAIN AXIS

The human gut microbiome is a complex community of microbes that play a key role in maintaining homeostasis. In addition to its well-established roles in digestion and nutrition, the gut microbiota has an impact on neurobiology via the gut-brain axis, controls the immune system, and defends against infections[3]. The symbiotic interaction between the gastrointestinal tract and the central nervous system is supported by a multitude of components, including microbial metabolites, immune substances, hormones, and neurons. Disturbances in the composition of microbial populations, known as microbial dysbiosis, can lead to a wide range of gastrointestinal, metabolic, and neurological diseases. Recent human studies have shown that gut microbiota

signals and gut pathogens have a substantial effect on brain activity, cognition, emotions, and disease susceptibility.

2.1. Composition and Functions of Human Gut Microbiota

Viruses, protozoa, fungi, bacteria, and archaea are just some of the microbes that call the human gastrointestinal system home. The most common phylum of microbes are the bacteria, followed by the firmicutes, bacteroidetes, actinobacteria, proteobacteria, and verrucomicrobia. The makeup of the gut microbiota can vary greatly from one person to another due to factors like age, genetics, nutrition, environment, medication, and many more.

Lots of things happen in the body because of the bacteria in the digestive tract. Because human digestive enzymes are unable to break down complex carbohydrates and dietary fibre, their metabolism presents one of these obstacles. Consequently, cells within the intestinal epithelium generate propionate, butyrate, and acetate, which are short-chain fatty acids. These acids are essential for the epithelium's energy needs and for keeping the immune system in check. Some vitamins, including vitamin K and several B vitamins, are synthesized by the microbiota, which is their second role.

Table 1: Major Gut Microbiota and Their Functions[4]

Microorganism	Major Function	Health Significance
Faecalibacterium prausnitzii	Butyrate production	Anti-inflammatory effects
Bifidobacterium spp.	Immune regulation	Gut barrier maintenance
Lactobacillus spp.	Pathogen inhibition	Improved gut health
Akkermansia muciniphila	Mucin degradation	Metabolic regulation
Roseburia spp.	SCFA production	Colon health

2.2. Major Gut Pathogens and Dysbiosis

An imbalance in the microbial community of the human gut in terms of either population dynamics, diversity, or functionality which leads to a deviation from the state of symbiosis between host and microorganisms is defined as dysbiosis. The possible causes for dysbiosis include antibiotics, poor diets, chronic stress, environment factors, infections, and lifestyle changes[5]. Dysbiosis includes a reduction in the number of good microorganisms and increase in the numbers of pathogenic ones, along with the change in the metabolic activities of the microbes.

There are certain microbes responsible for causing many GI disorders and other systemic diseases. Clostridioides difficile is a common cause of diarrhea and colitis linked with the use of antibiotics. Some strains of Escherichia coli, especially the AIEC strains, are known for causing CD and

inflammation of the intestines. Bacteroides fragilis is known to secrete toxins that can cause inflammation of the mucous membrane and contribute to CRC. Similarly, Fusobacterium nucleatum is increasingly being regarded as a microbial cause of CRC.

2.3. Molecular Mechanisms of Gut-Brain Communication

A number of metabolic, endocrine, immunological, and neurological processes are involved in the intricate process of bidirectional interaction that constitutes the gut-brain axis. It is through such interactions that gut bacteria affect brain activity while at the same time central nervous system controls gastrointestinal functions[6].

- **Neural Pathways:** Information mostly travels from the digestive tract to the central nervous system via the vagus nerve and the enteric nervous system. The vagus nerve is an important conduit for the transmission of signals between the gastrointestinal tract and the central nervous system. Gut microbes have the capability of producing certain metabolites and neurotransmitter-like substances that can influence the activity of vagal afferents, thus affecting mood, behavior and cognition. Enteric nervous system acts as an independent system that regulates motility, secretion and reflexes of the intestines, but at the same time, it has extensive communication with the central nervous system[7].
- **Immune Pathways:** The immunological response is an additional critical channel that allows the stomach and brain to communicate. Intestinal immune cells and the gut microbiota interact in ways that greatly affect inflammatory signaling and cytokine production. Interleukin-6, tum our necrosis factor alpha, and interleukin-1β are inflammatory cytokines that are released when dysbiosis occurs. It is possible for these immune system mediators to influence neuronal health via neural signaling or the blood-brain barrier.
- **Endocrine Pathways:** At its core, the endocrine branch of the gut-brain axis is hormone-mediated communication between the CNS, the GIT, and the gut microbiota. The HPA axis contributes significantly to the regulation of stress reactions. The HPA axis function can be affected by the gut microflora, which may regulate the production of cortisol and related stress pathway signalling. Additionally, enteroendocrine cells secrete a variety of hormones including GLP-1, PYY, and serotonin.
- **Metabolic Pathways:** One significant way that microorganisms help the stomach and brain communicate is by producing metabolites. A byproduct of microbial fermentation of dietary fibre, short chain fatty acids influence neuronal function and possess anti-inflammatory characteristics. Metabolites of tryptophan, produced by the bacteria present in the gut, control serotonin production and transmission. Other metabolites like those derived from bile acids and amino acids have the ability to affect brain signalling and development.

2.4. Human Clinical Evidence Linking Gut Microbiota and Neurological Health

The gut microbiota's role in neurological and psychological health is being supported by an increasing amount of data from human clinical trials[8]. Several lines of research have shown a link between alterations in the microbial community's variety and diseases such as MS, anxiety disorders, depression, ASD, Alzheimer's, and Parkinson's. Specifically, when compared to healthy individuals, patients with various disorders exhibit distinct microbial fingerprints.

In human cohorts, associations between gut microbiota diversity and cognitive skills, emotionality, and stress resistance were found. Reduced abundance of some beneficial genera of bacteria, such as Bifidobacterium and Lactobacillus, is related to psychological distress and symptoms of depression. Moreover, the analysis of the microbiome in combination with neuroimaging allowed finding associations between the composition of the microbial communities and brain structure and function.

Clinical treatments that target the gut bacteria have added credence to the gut-brain axis. There is a wide range of effectiveness among therapies such as dietary changes, probiotics, prebiotics, and FMT in reducing symptoms and changing neurologic outcome[9]. The gut microbiota appears to have a vital function in neurological health and illness, even if the relationship between the two is still being investigated in humans. Microbiome research, clinical practice, and computational methods must all work together for future advancements.

Table 2: Summary of Literature on Gut Microbiota Nexus and Human Health

Author(s)	Key Findings	Relevance to Present Study
Beaver et al. (2025)[10]	Gut microbiota and dietary phytochemicals promote healthy aging.	Highlights microbiota's role in overall health maintenance.
Chakraborty et al. (2024)[11]	Gut microbiota interacts with brain, heart, lung, and skin axes.	Supports the systemic effects of gut microbiota.
Gopal et al. (2024)[12]	Diet-induced microbial changes influence insulin resistance.	Demonstrates microbiota involvement in metabolic disorders.
Leao et al. (2025)[13]	Gut microbiota affects hormonal balance and mental health.	Strengthens evidence for the gut-brain axis.
Fu et al. (2023)[14]	Human, animal, and environmental microbiomes are interconnected.	Emphasizes the broader significance of microbiome research.

3. GLOBAL AND INDIAN EPIDEMIOLOGY OF GUT MICROBIOTA-ASSOCIATED DISORDERS

Disorders due to gut microbiota, specifically IBD and CRC, are serious public health issues all around the world. Various factors such as industrialization, urbanization, change in diets, exposure to environment, and change in lifestyles have resulted in marked changes in the composition of human gut microbiota. The role of microbial dysbiosis in intestinal inflammation and carcinogenesis has been proved time and again and hence epidemiological evaluation of the said disorders is crucial. Previously, these diseases used to be common in Western countries; however, in recent years there has been an increase in the incidence and prevalence of these diseases among developing countries including India.

3.1. Global Epidemiology of Inflammatory Bowel Disease

IBD include CD and UC that are accompanied by inflammatory attacks in the gastrointestinal tract. During recent decades, there was an increase in the burden of IBD on the population around the world, especially in developed parts of North America, Western Europe, and Oceania. These areas maintain the highest prevalence rates of this disease caused by long-term effects of the environment and way of life that can lead to disease development.

According to epidemiological research, IBD is changing from the disease that mainly occurs in the West to the global issue due to rising rates of incidence in newly developed countries located in Asia, South America, and the Middle East. The reasons for epidemiology shift in IBD development include changes in diet, antibiotics usage, urbanization, decreased biodiversity, better recognition and diagnosis of IBD. Moreover, recent data show that changes in the composition of gut microbiota could be responsible for the disease development due to its effects on the immune system.

3.2. Global Epidemiology of Colorectal Cancer

Colorectal carcinoma is one of the most frequently diagnosed malignancies globally and also the most significant contributor to the mortality rate from cancers. There has been an increasing trend in the incidence of colorectal carcinoma over the recent years. However, there is significant geographical variation in the prevalence of the disease. Developed nations have always exhibited the highest burden of the disease; however, there is also an increase in the prevalence of the disease among several developing nations.

Various epidemiological studies have shown the association between CRC and diet which include eating a lot of processed food, red meats, high saturated fats and minimal fiber in diet. Such dietary modifications result in changes in gut microbiota. This leads to development of chronic inflammation, generation of carcinogenic compounds and alteration in the integrity of the bowel

walls. Various bacterial species such as F. nucleatum, enterotoxigenic Bacteroides fragilis, some E. coli strains are known for their association with CRC through inflammatory processes and genotoxicity.

3.3. Epidemiological Trends in India

India is undergoing a major epidemiological shift, marked by urbanization, changes in eating habits, alteration in the environment, and an increased occurrence of chronic non-communicable diseases. All of these have led to an increase in gut microbiota-related diseases, like IBD and CRC.

- **Crohn's Disease:** Once regarded as rare in India, CD has demonstrated an increase in its frequency and prevalence over the last few decades. The advances in diagnostic methods and increased awareness of the disease have facilitated the identification of more individuals with this condition. It seems that urban people demonstrate a higher disease prevalence compared to rural populations owing to differences in lifestyles, diets, sanitation, and microbiological factors. Indian individuals suffering from CD typically show symptoms characteristic of Western populations, despite some regional variability in the disease manifestation. The increase in the number of cases of CD can be explained by the increased tendency to consume Western-like diet including processed foods and foods containing high amounts of carbohydrates and low fiber content. This change in diets can influence the microflora of the intestines and induce chronic inflammation.
- **Ulcerative Colitis:** UC still happens to be the most frequent type of IBD in India. Researches in the field show a consistent growth in the number of patients suffering from the disease in both urban and semi-urban areas. Medical care facilities along with the development of endoscopic diagnostics have made it possible to detect and correctly diagnose the condition at an earlier stage. Some researches prove that the environment and microflora of the gastrointestinal tract are very important factors that contribute to UC development in India. Variations in hygiene, antibiotic administration, diet, and the environment can affect the composition of the microflora and the immune system, thus causing this disease. The growing number of patients requires the development of effective public health measures.
- **Colorectal Cancer:** Although the incidence of CRC cases in India is still relatively low compared with those seen in many Western countries, an increasing trend has been noted over the past few decades. Urban and economically advanced areas show a higher rate of incidence due to changes in lifestyle and dietary habits. Eating more processed foods, a lack of exercise, being obese, and having a sedentary lifestyle are considered important risk factors for developing CRC.

Several reports indicate the significant role played by the microbial imbalance in the development of CRC in India. Changes in the microbial environment in the gut may result in chronic

inflammation, immune dysregulation, and the generation of tumor-forming agents. Delayed diagnosis and poor participation in screening programs continue to be major problems in India.

3.4. Environmental and Lifestyle Determinants

Environmental and behavioral factors have a major impact on microbiome structure and serve as essential factors in the development of IBD and CRC. One of the main factors affecting gut flora composition is diet. High consumption of fruits, vegetables, whole grain, and fiber results in the proliferation of beneficial microorganisms and the formation of metabolites that decrease inflammation. On the contrary, consumption of processed foods, sugar, saturated fat, and meat typical of westernized diets leads to dysbiosis and disease development.

Another crucial factor affecting microbiome composition is the use of antibiotics. Overuse or misuse of antibiotics causes decreased diversity of gut flora and disturbance of protective microbial communities thus making people more prone to gastrointestinal diseases. Urbanization, pollution, smoking, drinking, stress, and inactive lifestyle are the other factors associated with microbiota dysbiosis and diseases such as inflammation and malignancy.

Furthermore, early life exposures including the type of birth delivery, breastfeeding, hygiene conditions, and socioeconomic status play an essential role in the development and maintenance of gut microbiome. These factors affect interactions between humans and microbes and might explain the regional differences in diseases prevalence and outcomes. It is necessary to comprehend the impact of environmental and behavioral factors on microbiome for developing efficient preventative measures and personalized interventions for reducing the burden of diseases associated with microbiome.

4. GUT MICROBIOTA IN INFLAMMATORY BOWEL DISEASE AND COLORECTAL CANCER

Gut microbiota is responsible for regulating intestinal homeostasis and immune system functionality, as well as preventing pathogen invasions[15]. Dysbiosis, which is defined as an imbalance between the number of good and pathogenic microbes, is closely related to IBD and CRC. Patients suffering from either CD or UC show a lack of biodiversity in the gut, depletion of beneficial bacteria, such as Faecalibacterium prausnitzii, Bifidobacterium, and Lactobacillus, and presence of more pathogenic microorganisms.

In case of CRC, some of the pathogenic bacteria, like Fusobacterium nucleatum, enterotoxigenic Bacteroides fragilis, and strains of Escherichia coli, are linked with the development and growth of tumor in colorectum. Pathogenic microorganisms act as carcinogens causing inflammation, immunological response, DNA damage, and proliferation. At the same time, new developments in microbiome sequencing techniques make it possible to use AI and multiple-omics to detect potential biomarkers of the disease.

With the recent researches proving the significance of the microbiome for the proper diagnosis and treatment of many conditions, numerous therapeutical methods using the microbiome are developed. Probiotics, prebiotics, symbiotic, and FMT are the most popular techniques aimed at the restoration of gut flora balance and improvement of intestines health and reduction of inflammation.

5. ARTIFICIAL INTELLIGENCE IN GUT MICROBIOME RESEARCH

AI is currently used extensively in the study of gut microorganisms as an aid in the processing of big and complicated biological datasets using metagenomic, transcriptomic, proteomic, metabolomic, and clinical investigations[16]. AI and machine/deep learning assist in the recognition of microorganism fingerprints, finding biomarkers, classifying diseases and personalized therapies. They are changing the field of gastroenterology and providing new methods to study IBD, CRC, and other diseases related to the gut microbiome.

AI analysis can be used in microbiome data analysis for discovering the patterns of microbial organisms and the integration of several biological datasets to make a predictive model. The application of AI in IBD includes diagnostics of the disease, estimation of its seriousness, relapses, treatment, and automatic image analyses from endoscopic/histopathologic examination. Also, AI is helpful in early diagnostics and prognosis of CRC through microbiome-derived biomarkers, individual treatment plans, and high accuracy of colonoscopy screening tests[17].

Although there is much promise for precision medicine powered by AI, the current issues faced include variable microbiome data, lack of explainability of models, privacy of data, and clinical validation on a large scale[18]. However, developments such as explainable AI, integration of multiple omics approaches, and standardization of microbiome databases are likely to increase clinical relevance in the future[19]. On the whole, the application of AI and microbiome research is advancing personalized medicine for gastrointestinal disorders[20].

6. FROM CODE TO LIVING TISSUE: HUMAN ORGANOIDS AND 3D BIOPRINTING

The integration of AI with tissue engineering, stem cell biology, and regenerative medicine is bringing a new wave of innovations in biomedical science, known as the evolution of biomedical research "from biological code to living tissue[21]." While the advances in genomics, microbiomics, and AI analysis allow understanding the mechanisms of diseases on a molecular level, the conversion of these results into meaningful models necessitates sophisticated biological platforms that will be able to mimic human biology[22]. One of such platforms is represented by human intestinal organoids and 3D bioprinting technology, which are considered transformative technologies that provide an opportunity for creating specific patient-tailored tissue models for the study of the disease, drug testing, and regenerative purposes[23]. These technologies are especially important in the context of IBD and CRC, as there is a complicated interplay between host organs, immune system, bacteria, and the environment, which determines the course of these diseases.

Organoids and 3D printed tissues give a unique opportunity for precision medicine and translational gastroenterology[24].

6.1. Fundamentals of 3D Bioprinting

Three-dimensional bioprinting is a sophisticated method of biofabrication whereby living tissues can be fabricated through deposition of cells, biomaterials, and bioactive molecules layer by layer[25]. Bioprinting differs from conventional 3D printing since it involves biological substances (bioinks) that are capable of being incorporated into living tissues rather than non-living materials such as plastics or metals used in traditional 3D printing[26].

Different bioprinting technologies are currently available for tissue engineering applications. Inkjet bioprinting involves precise deposition of droplets of bioinks containing live cells. Extrusion-based bioprinting involves deposition of biomaterials continuously in order to fabricate bigger tissue constructs[27]. Laser-assisted bioprinting applies the principle of positioning cells using laser energy with high precision and viability. All three technologies are associated with different strengths according to complexity of tissue engineering application.

Some critical factors are involved in successful bioprinting and include cell viability, properties of bioinks, structural stability, vascularization, and functional integration. With advances in the field of biomaterials, stem cell technology, and design methods, it became possible to create more biologically relevant models[28]. Hence, 3D bioprinting represents a promising technology for creating human tissues and modeling diseases in laboratory conditions[29].

6.2. Human Intestinal Organoids and Patient-Derived Models

Human intestinal organoids are three-dimensional self-assembling cellular structures derived from human stem cells, which very much resemble the structural and functional features of the native intestine[30]. The miniaturized tissue system comprises different intestinal cell types like enterocytes, goblet cells, Paneth cells, and enteroendocrine cells, hence allowing them to mimic the physiological process seen in vivo.

Organoids can be created using iPSCs, embryonic stem cells, or adult stem cells derived from patient biopsies[31]. The patient-derived organoids retain many genetic and functional features of the native tissue, thus making them ideal for disease models and therapeutic studies.

In gastrointestinal research, human intestinal organoids have changed the way scientists conduct studies related to the host-microbiota interaction, epithelial barrier, inflammation, and cancers[32]. In contrast to conventional 2D cell cultures, the organoid system provides a physiological environment where scientists can analyze the disease mechanisms at the cellular and molecular level. In addition, patient-derived organoids allow for the individualized assessment of therapies since one can evaluate the reaction of the patient to the administered drugs.



Figure 2: Intestinal Organoids[33]

6.3. Human 3D Bioprinted Gut Tissues

Despite having significantly advanced disease modeling, organoids suffer from several drawbacks pertaining to structure, vasculature, and reproducibility[34]. Bioprinting of engineered tissues with the help of three-dimensional bioprinting technologies solves many of the aforementioned problems by allowing for the creation of engineered tissues with the necessary architecture and cellular content.

Bioprinted human gut tissues have been engineered to replicate important structural and functional aspects of the intestine wall, such as epithelial layers, stroma, and extracellular matrix architecture. Inclusion of different cells in bioink enables the construction of tissues that better mimic human native environment[35].

These bioprinted tissues serve as a good model to investigate physiology of the intestinal tissues, barrier function, microbial interactions, and pathogenesis[36]. Patient-specificity is achieved by the use of patient-derived cells in tissue engineering, which enables the creation of personalized tissue

models and, therefore, has an enormous impact on the development of personalized medicine and the investigation of complex diseases like IBD and CRC.

6.4. Applications in Crohn's Disease and Ulcerative Colitis

Both CD and UC manifest themselves in chronic inflammation of the intestine caused by the interaction between genetic, immunological, microbial, and environmental elements[37]. Classic experimental animal models do not completely mimic all characteristics of human disease due to its heterogeneous nature; therefore, they create difficulties in researching the process of disease development and testing new therapies[38].

In turn, human intestinal organoids have proved to be very useful in studying the molecular mechanisms of IBD. In fact, using patient-derived organoids allows scientists to investigate their disease-related genes and epigenetics, and analyze such processes as epithelial dysfunction and inflammatory signalling pathways and host-microbiota interaction in vitro.

3D bioprinting is another technology that helps recreate the diseased environment in vitro and investigate possible treatments of intestinal inflammation using this system. In this way, it is possible to combine immune cells, epithelial cells, and factors produced by bacteria in order to mimic the disease in vitro and test potential treatment options.

Thus, the combination of organoid technology and 3D bioprinting with AI-assisted data analysis allows developing better methods of treating patients with IBD.

Table 3: Human Organoids and 3D Bioprinting Applications[39]

Technology	Application	Clinical Relevance
Human Intestinal Organoids	Disease modeling	Personalized medicine
Patient-Derived Organoids	Drug screening	Treatment optimization
3D Bioprinted Gut Tissues	Tissue engineering	Regenerative medicine
Bioprinted Tumor Models	Cancer research	Precision oncology

7. DISCUSSION AND FUTURE PERSPECTIVES

The present review emphasizes the significance of research on gut microbiota in gastrointestinal disorders pathobiology, diagnosis and therapy. New technologies like artificial intelligence (AI), human organoids, and 3D bioprinting have offered opportunities to explore the intricate interactions between host and microorganisms and precision medicine strategies. Combining the fields of microbiome science, computational and bioengineering, researchers are developing a deeper understanding of inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative

colitis (UC), and colorectal cancer (CRC) which could lead to new and improved diagnostics and therapeutics.

7.1.Interpretation and Analysis of the Findings

This review confirmed that gut microbiota is a critical player in gastrointestinal, metabolic, immunological, and neurological functions. Changes in the composition of microorganisms, known as dysbiosis, are closely linked to inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), and to colorectal cancer (CRC). The authors point out that disrupted microbial ecology, such as decreased beneficial microorganisms and increased pathogenic microorganisms, and altered microbial metabolic functions are fundamentally linked to chronic inflammation, immune dysfunction, disruption of the epithelial barrier, and gut-brain axis dysfunction[40]. In addition, certain organisms (e.g., Fusobacterium nucleatum, adherent-invasive Escherichia coli (AIEC), enterotoxigenic Bacteroides fragilis) have consistently been associated with the progression of disease and carcinogenesis. The results also indicate that AI-based technologies could successfully leverage the vast amounts of complex microbiome data, detect disease-associated biomarkers and enhance disease prediction models. In addition, human intestinal organoids and 3D bioprinted tissues provide advanced experimental platforms that enable researchers to investigate disease mechanisms and validate therapeutic strategies under physiologically relevant conditions.

7.2. Implications and Significance

The combination of gut microbiota research and the potential use of 3D bioprinting and AI in the field of gastroenterology is poised to transform the precision medicine landscape in the future. IBD and CRC patients have great potential for using microbiome-based biomarkers for non-invasive diagnosis, early disease detection, prognosis and disease monitoring. Analytical systems powered by AI can process vast amounts of biological information and aid in personalized therapy choices. In addition, human organoids and bioprinted tissues are revolutionary tools for disease modelling, drug testing, regenerative medicine, and the evaluation of treatment in individual patients. These technologies can help to create a more complete picture of disease pathogenesis and enable the development of personalized healthcare strategies that could yield better outcomes for patients and help lower the global burden of gastrointestinal diseases.

7.3. Research Gaps and Future Research Directions

Although there are significant advances, there are a few challenges in microbiome studies and clinical applications. Studies conducted at present do not always employ standard sampling or sequencing methods, nor do they always employ the same bioinformatics analyses, nor do they always have the same population characteristics, which means that results vary. The majority of investigations that are available are cross-sectional, which means that cause-and-effect relationships between the development of disease and microbial dysbiosis cannot be drawn.

Moreover, numerous AI models are considered "black-box" systems that lack clinical interpretability and transparency, and the datasets commonly used are geographically limited and lack proper diversity. Other limitations of current organoid and 3D bioprinting models are vascularization, integration of immune system, inclusion of microbiome, and long-term functionality. Large-scale, longitudinal studies are required in the future to confirm the use of microbial biomarkers and to elucidate disease mechanisms. There is also a need to push forward the explainable AI systems, multi-omics data platforms, organoid and bioprinting technologies, and employing patient-derived models for personalized therapy testing. There is still much to be explored about the gut-brain axis, digital twin technologies and the interdisciplinary partnerships that can help further the precision gastroenterology paradigm and make these innovations a reality for clinical practice.

8. CONCLUSION

The present review sheds light on the complex interrelationship between gut microbiota, pathogens, gut-brain axis, AI, and 3D bioprinting in the context of IBD, CD, UC, and CRC. The findings discussed show that gut microbiota performs a critical function in terms of maintaining physiological well-being, whereas its dysbiosis has an impact on the progression of various diseases via inflammation, immune disorders, and disturbed gut-brain interaction. At the same time, it is stated that new approaches, like the use of AI for biomarker discovery, disease prediction, and personalized treatment planning and development of human organoids and 3D bioprinting techniques, help researchers to study microorganism's influence on health in more detail. Thus, this review emphasizes the relevance of combining advances in microbiome science, computational intelligence, and tissue engineering. In order to exploit the clinical capabilities of mentioned innovations fully, the future research should concentrate on standardization of microbiome research techniques, longitudinal studies, development of interpretable AI, and improvement of organoids and bioprinting models to mimic human physiology more effectively.

REFERENCES

1. Bhattarai, S., & Janaswamy, S. (2022). The nexus of gut microbiota, diet, and health. Functional Food Science-Online ISSN: 2767-3146, 2(2), 47-63.
2. He, Y., Fu, B., Fang, C., Zhang, N., Zheng, M., Yang, Y., ... & Yang, H. (2025). Decoding the gut-microbiota-muscle nexus: Multi-omics integration reveals mTOR driven flesh modulation in rice-fish co-cultured common carp (Cyprinus carpio). Aquaculture, 743090.
3. Mahboob, A., Shin, C., Almughanni, S., Hornakova, L., Kubatka, P., & Büsselberg, D. (2025). The Gut Nexus: Unraveling Microbiota-Mediated Links Between Type 2 Diabetes and Colorectal Cancer. Nutrients, 17(23), 3803.

4. Swamikkannu, D. M., Dasarapu, S., Siva, R. P. V., Nallam, J., & Pabba, S. (2024). The gut-liver nexus: exploring gut microbiota dysbiosis in non-alcoholic fatty liver disease and its therapeutic implications. Egyptian Liver Journal, 14(1), 28.
5. Sundman, M. H., Chen, N. K., Subbian, V., & Chou, Y. H. (2017). The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease. Brain, behavior, and immunity, 66, 31-44.
6. Chattopadhyay, I., & Shankar, E. M. (2021). SARS-CoV-2-indigenous microbiota nexus: does gut microbiota contribute to inflammation and disease severity in COVID-19?. Frontiers in cellular and infection microbiology, 11, 590874.
7. Ray, G. (2016). Inflammatory bowel disease in India-Past, present and future. World journal of gastroenterology, 22(36), 8123.
8. Dharni, K., Singh, A., Sharma, S., Midha, V., Kaur, K., Mahajan, R., ... & Sood, A. (2024). Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019). Indian Journal of Gastroenterology, 43(1), 188-198.
9. Giri, S., Jena, A., Kumar-M, P., Muniswamy, J. R., Nath, P., & Sharma, V. (2025). Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019. Intestinal Research.
10. Beaver, L. M., Jamieson, P. E., Wong, C. P., Hosseinikia, M., Stevens, J. F., & Ho, E. (2025). Promotion of healthy aging through the nexus of gut microbiota and dietary phytochemicals. Advances in Nutrition, 16(3), 100376.
11. Chakraborty, P., Banerjee, D., Majumder, P., & Sarkar, J. (2024). Gut microbiota nexus: Exploring the interactions with the brain, heart, lungs, and skin axes and their effects on health. Medicine in Microecology, 20, 100104.
12. Gopal, R. K., Ganesh, P. S., & Pathoor, N. N. (2024). Synergistic interplay of diet, gut microbiota, and insulin resistance: Unraveling the molecular nexus. Molecular Nutrition & Food Research, 68(23), 2400677.
13. Leao, L., Miri, S., & Hammami, R. (2025). Gut feeling: exploring the intertwined trilateral nexus of gut microbiota, sex hormones, and mental health. Frontiers in Neuroendocrinology, 76, 101173.
14. Fu, Y., Dou, Q., Smalla, K., Wang, Y., Johnson, T. A., Brandt, K. K., ... & Tiedje, J. M. (2023). Gut microbiota research nexus: One Health relationship between human, animal, and environmental resistomes. Mlife, 2(4), 350-364.
15. Jain, M., & Venkataraman, J. (2021). Inflammatory bowel disease: An Indian perspective. Indian Journal of Medical Research, 153(4), 421-430.
16. Sood, A., Kaur, K., Mahajan, R., Midha, V., Singh, A., Sharma, S., ... & Rao, N. S. (2021). Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry. Intestinal research, 19(2), 206-216.

17. Banerjee, R., Pal, P., Patel, R., Godbole, S., Komawar, A., Mudigonda, S., ... & Travis, S. P. (2023). Inflammatory bowel disease (IBD) in rural and urban India: results from community colonoscopic evaluation of more than 30,000 symptomatic patients. The Lancet Regional Health-Southeast Asia, 19.

18. Palandurkar, G. S., & Kumar, S. (2023). Biofilm's impact on inflammatory bowel diseases. Cureus, 15(9).

19. Snell, A., Segal, J., Limdi, J., & Banerjee, R. (2021). Inflammatory bowel disease in India: challenges and opportunities. Frontline Gastroenterology, 12(5), 390-396.

20. Malhotra, R., Turner, K., Sonnenberg, A., & Genta, R. M. (2015). High prevalence of inflammatory bowel disease in United States residents of Indian ancestry. Clinical Gastroenterology and Hepatology, 13(4), 683-689.

21. Saeed, S. A., & Kugathasan, S. (2017). Epidemiology of pediatric inflammatory bowel disease. In Pediatric inflammatory bowel disease (pp. 71-86). Cham: Springer International Publishing.

22. Parikh, K., Antanaviciute, A., Fawkner-Corbett, D., Jagielowicz, M., Aulicino, A., Lagerholm, C., ... & Simmons, A. (2019). Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature, 567(7746), 49-55.

23. Yao, D., Dong, M., Dai, C., & Wu, S. (2019). Inflammation and inflammatory cytokine contribute to the initiation and development of ulcerative colitis and its associated cancer. Inflammatory bowel diseases, 25(10), 1595-1602.

24. Stidham, R. W., & Higgins, P. D. (2018). Colorectal cancer in inflammatory bowel disease. Clinics in colon and rectal surgery, 31(03), 168-178.

25. Hnatyszyn, A., Hryhorowicz, S., Kaczmarek-Ryś, M., Lis, E., Słomski, R., Scott, R. J., & Pławski, A. (2019). Colorectal carcinoma in the course of inflammatory bowel diseases. Hereditary cancer in clinical practice, 17(1), 18.

26. Shahgoli, V. K., Noorolyai, S., Ahmadpour Youshanlui, M., Saeidi, H., Nasiri, H., Mansoori, B., ... & Baradaran, B. (2024). Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link. International journal of colorectal disease, 39(1), 173.

27. Qiu, W., Akanyibah, F. A., Xia, Y., Ocansey, D. K. W., Mao, F., & Liang, Y. (2024). Emerging role of small RNAs in inflammatory bowel disease and associated colorectal cancer. International Journal of Molecular Medicine, 55(2), 33.

28. Birch, R. J., Burr, N., Subramanian, V., Tiernan, J. P., Hull, M. A., Finan, P., ... & Morris, E. J. (2022). Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: an English population-based study. Official journal of the American College of Gastroenterology| ACG, 117(11), 1858-1870.

29. Sæterstad, S., Østvik, A. E., Røyset, E. S., Bakke, I., Sandvik, A. K., & Granlund, A. V. B. (2022). Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn's disease. PloS one, 17(3), e0265189.

30. Bojesen, R. D., Riis, L. B., Høgdall, E., Nielsen, O. H., & Jess, T. (2017). Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study. Clinical gastroenterology and hepatology, 15(12), 1900-1907.

31. Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N., & Hanhineva, K. (2022). Microbiota-derived metabolites as drivers of gut–brain communication. Gut microbes, 14(1), 2102878.

32. Fung, T. C. (2020). The microbiota-immune axis as a central mediator of gut-brain communication. Neurobiology of disease, 136, 104714.

33. Aburto, M. R., & Cryan, J. F. (2024). Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis. Nature reviews Gastroenterology & hepatology, 21(4), 222-247.

34. Zinkow, A., Grodzicki, W., Czerwińska, M., & Dziendzikowska, K. (2024). Molecular mechanisms linking omega-3 fatty acids and the gut–brain axis. Molecules, 30(1), 71.

35. Spencer, N. J., Hibberd, T. J., & Hu, H. (2026). Gut–brain communication: types of sensory nerves and mechanisms of activation. Nature Reviews Gastroenterology & Hepatology, 23(2), 145-165.

36. Chen, C., Wang, G. Q., Li, D. D., & Zhang, F. (2025). Microbiota–gut–brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Molecular biomedicine, 6(1), 64.

37. Keightley, P. C., Koloski, N. A., & Talley, N. J. (2015). Pathways in gut-brain communication: evidence for distinct gut-to-brain and brain-to-gut syndromes. Australian & New Zealand Journal of Psychiatry, 49(3), 207-214.

38. Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. Frontiers in endocrinology, 11, 508738.

39. Ortlek, B. E., & Akan, O. B. (2025). Modeling and Analysis of SCFA-Driven Vagus Nerve Signaling in the Gut-Brain Axis via Molecular Communication. IEEE Transactions on Molecular, Biological, and Multi-Scale Communications.

40. Boris, V., & Vanessa, V. (2023). Molecular systems biology approaches to investigate mechanisms of gut− brain communication in neurological diseases. European Journal of Neurology, 30(11), 3622-3632.